Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials
- PMID: 26754058
- PMCID: PMC4709689
- DOI: 10.1038/srep19188
Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials
Abstract
We aimed to assess the impact of L-carnitine on plasma Lp(a) concentrations through systematic review and meta-analysis of available RCTs. The literature search included selected databases up to 31(st) January 2015. Meta-analysis was performed using fixed-effects or random-effect model according to I(2) statistic. Effect sizes were expressed as weighted mean difference (WMD) and 95% confidence interval (CI). The meta-analysis showed a significant reduction of Lp(a) levels following L-carnitine supplementation (WMD: -8.82 mg/dL, 95% CI: -10.09, -7.55, p < 0.001). When the studies were categorized according to the route of administration, a significant reduction in plasma Lp(a) concentration was observed with oral (WMD: -9.00 mg/dL, 95% CI: -10.29, -7.72, p < 0.001) but not intravenous L-carnitine (WMD: -2.91 mg/dL, 95% CI: -10.22, 4.41, p = 0.436). The results of the meta-regression analysis showed that the pooled estimate is independent of L-carnitine dose (slope: -0.30; 95% CI: -4.19, 3.59; p = 0.878) and duration of therapy (slope: 0.18; 95% CI: -0.22, 0.59; p = 0.374). In conclusion, the meta-analysis suggests a significant Lp(a) lowering by oral L-carnitine supplementation. Taking into account the limited number of available Lp(a)-_targeted drugs, L-carnitine might be an effective alternative to effectively reduce Lp(a). Prospective outcome trials will be required to fully elucidate the clinical value and safety of oral L-carnitine supplementation.
Figures
Similar articles
-
Effect of garlic on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled clinical trials.Nutrition. 2016 Jan;32(1):33-40. doi: 10.1016/j.nut.2015.06.009. Epub 2015 Jul 17. Nutrition. 2016. PMID: 26522661 Review.
-
Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials.Metabolism. 2016 Nov;65(11):1664-1678. doi: 10.1016/j.metabol.2016.08.007. Epub 2016 Aug 31. Metabolism. 2016. PMID: 27733255 Review.
-
The effect of l-carnitine supplementation on lipid profile and glycaemic control in adults with cardiovascular risk factors: A systematic review and meta-analysis of randomized controlled clinical trials.Clin Nutr. 2020 Jan;39(1):110-122. doi: 10.1016/j.clnu.2019.01.020. Epub 2019 Feb 22. Clin Nutr. 2020. PMID: 30850271
-
The effects of carnitine supplementation on clinical characteristics of patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.Complement Ther Med. 2020 Jan;48:102273. doi: 10.1016/j.ctim.2019.102273. Epub 2019 Nov 29. Complement Ther Med. 2020. PMID: 31987257
-
Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis.Pharmacol Res. 2016 Mar;105:198-209. doi: 10.1016/j.phrs.2016.01.030. Epub 2016 Feb 2. Pharmacol Res. 2016. PMID: 26836888 Review.
Cited by
-
L-Carnitine's Effect on the Biomarkers of Metabolic Syndrome: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Nutrients. 2020 Sep 12;12(9):2795. doi: 10.3390/nu12092795. Nutrients. 2020. PMID: 32932644 Free PMC article.
-
The ins and outs of lipoprotein(a) assay methods.Arch Med Sci Atheroscler Dis. 2023 Dec 30;8:e128-e139. doi: 10.5114/amsad/176653. eCollection 2023. Arch Med Sci Atheroscler Dis. 2023. PMID: 38283929 Free PMC article.
-
L-Carnitine/Simvastatin Reduces Lipoprotein (a) Levels Compared with Simvastatin Monotherapy: A Randomized Double-Blind Placebo-Controlled Study.Lipids. 2017 Jan;52(1):1-9. doi: 10.1007/s11745-016-4216-z. Epub 2016 Dec 2. Lipids. 2017. PMID: 27914033 Clinical Trial.
-
Association of Low Serum l-Carnitine Levels with Aortic Stiffness in Patients with Non-Dialysis Chronic Kidney Disease.Nutrients. 2020 Sep 24;12(10):2918. doi: 10.3390/nu12102918. Nutrients. 2020. PMID: 32987670 Free PMC article.
-
Risk burdens of modifiable risk factors incorporating lipoprotein (a) and low serum albumin concentrations for first incident acute myocardial infarction.Sci Rep. 2016 Oct 17;6:35463. doi: 10.1038/srep35463. Sci Rep. 2016. PMID: 27748452 Free PMC article.
References
-
- Marcovina S. M., Koschinsky M. L., Albers J. J. & Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein (a) and Cardiovascular Disease: recent advances and future directions. Clinical chemistry 49, 1785–1796 (2003). - PubMed
-
- Ramasamy I. Recent advances in physiological lipoprotein metabolism. Clinical Chemistry and Laboratory Medicine (CCLM) 52, 1695–1727 (2014). - PubMed
-
- Clarke R. et al. Genetic variants associated with Lp (a) lipoprotein level and coronary disease. New England Journal of Medicine 361, 2518–2528 (2009). - PubMed
-
- Lippi G. & Guidi G. Biochemical risk factors and patient’s outcome: the case of lipoprotein (a). Clinica chimica acta 280, 59–71 (1999). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous